Payment overview · 2025
General Payments
$223.61
12 reported records · 7 companies
Healthcare provider profile · identity verified
Harry A Carter, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FLORA, IL · NPI 1538165261
Verified facts
What the public records show
CMS Open Payments records show Harry A Carter, M.D. received $223.61 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.58 | 24.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.44 | 22.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.94 | 14.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.58 | 13.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.49 | 8.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.18 | 8.1% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $17.40 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $223.61 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $55.58 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $50.44 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 56 |
| Lisinopril | Lisinopril | 208 | 48 |
| Losartan Potassium | Losartan Potassium | 194 | 57 |
| Potassium Chloride | Potassium Chloride | 190 | 44 |
| Omeprazole | Omeprazole | 164 | 40 |
| Furosemide | Furosemide | 150 | 35 |
| Jardiance | Empagliflozin | 141 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 32 |
| Trulicity | Dulaglutide | 113 | 17 |
| Metformin Hcl | Metformin Hcl | 104 | 22 |
| Ozempic | Semaglutide | 95 | 15 |
| Eliquis | Apixaban | 92 | 22 |
| Tramadol Hcl | Tramadol Hcl | 88 | 25 |
| Gabapentin | Gabapentin | 86 | 20 |
| Prednisone | Prednisone | 85 | 35 |
| Famotidine | Famotidine | 83 | 16 |
| Pregabalin | Pregabalin | 83 | 12 |
| Carvedilol | Carvedilol | 78 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 69 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 15 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | suppressed |
| Simvastatin | Simvastatin | 64 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 18 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 19 |
| Azithromycin | Azithromycin | 56 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 13 |
| Montelukast Sodium | Montelukast Sodium | 50 | 14 |
| Alprazolam | Alprazolam | 49 | 13 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Trazodone Hcl | Trazodone Hcl | 41 | suppressed |
| Lorazepam | Lorazepam | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 29 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nystatin | Nystatin | 20 | 16 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 18 |
| Fluconazole | Fluconazole | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Baclofen | Baclofen | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 14 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $223.61 · 12 records | AstraZeneca Pharmaceuticals LP | ABILIFY MAINTENA, BREZTRI, Cologuard Collection Kit, FANAPT, LYBALVI, REXULTI, WatchPATONE | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error